Compare Danaos Corporation (DAC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Sana Biotechnology Inc — how do they compare? Danaos Corporation trades at $138.94 (market cap $2.46B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Danaos Corporation is far larger — about 2.2× Sana Biotechnology Inc's market cap, and Danaos Corporation pays a 2.67% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DAC | SANA | |
|---|---|---|
Market Cap | $2.46B | $1.13B |
Sector | Technology | Health |
52-Week High | $143.15 | $5.92 |
52-Week Low | $84.05 | $2.68 |
Enterprise Value | $2.44B | $1.05B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $138.94, up 0.45% today, with a bullish technical signal supported by moving averages and oversold RSI indicators. The stock shows strong fundamentals with a low P/E of 4.57, robust net income margin of 51.26%, and consistent earnings beats in recent quarters. Recent news highlights record contracted revenue backlog and dividend declarations, reinforcing positive momentum.
Outlook remains favorable due to undervaluation and earnings strength, but risks include shipping market volatility and capital expenditure pressures. Analyst consensus is split evenly between Buy and Hold, indicating cautious optimism for continued growth amid sector-specific challenges.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
